NCT01383499 - A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Asthma

Interventions

DRUG

Tiotropium bromide

inhalation solution administered via Respimat in 3 different doses

DRUG

Tiotropium bromide

inhalation solution administered via Respimat in 3 different doses

DRUG

Tiotropium bromide

inhalation solution administered via Respimat in 3 different doses

DRUG

Tiotropium bromide

inhalation solution administered via Respimat in 3 different doses

Trial Locations (24)

Unknown

205.425.49005 Boehringer Ingelheim Investigational Site, Bochum

205.425.49004 Boehringer Ingelheim Investigational Site, Dresden

205.425.49002 Boehringer Ingelheim Investigational Site, Koblenz

205.425.36001 Boehringer Ingelheim Investigational Site, Budapest

205.425.36003 Boehringer Ingelheim Investigational Site, Budapest

205.425.36002 Boehringer Ingelheim Investigational Site, Mosdós

205.425.36004 Boehringer Ingelheim Investigational Site, Szeged

205.425.37101 Boehringer Ingelheim Investigational Site, Baldone

205.425.37105 Boehringer Ingelheim Investigational Site, Balvi

205.425.37104 Boehringer Ingelheim Investigational Site, Daugavpils

205.425.37106 Boehringer Ingelheim Investigational Site, Dubulti

205.425.37102 Boehringer Ingelheim Investigational Site, Riga

205.425.37103 Boehringer Ingelheim Investigational Site, Riga

205.425.37004 Boehringer Ingelheim Investigational Site, Kaunas

205.425.37003 Boehringer Ingelheim Investigational Site, Tauragė

205.425.37001 Boehringer Ingelheim Investigational Site, Vilnius

205.425.37002 Boehringer Ingelheim Investigational Site, Vilnius

205.425.07003 Boehringer Ingelheim Investigational Site, Moscow

205.425.07004 Boehringer Ingelheim Investigational Site, Moscow

205.425.07001 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.425.07002 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.425.38002 Boehringer Ingelheim Investigational Site, Donetsk

205.425.38004 Boehringer Ingelheim Investigational Site, Kiev

205.425.38003 Boehringer Ingelheim Investigational Site, Zaporizhya